Skip to search formSkip to main contentSkip to account menu

1 ML TALIMOGENE LAHERPAREPVEC 100000000 UNT Injection

Known as: TALIMOGENE LAHERPAREPVEC 100 MILLION PFU/ML INJ,SUSP,1ML,VIL, TALIMOGENE LAHERPAREP 100 MIL PFU/ML 1ML, talimogene laherparepvec 100,000,000 PFU per 1 ML Injection 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

1 ML TALIMOGENE LAHERPAREPVEC 100000000 UNT Injection [Imlygic]
InjectionTALIMOGENE LAHERPAREPVEC

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
Review
2019
Review
2019
Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety.
Intratumoral immunotherapy inhibits tumor growth by killing injected tumor cells, thus initiating local and systemic immune… 
Review
2018
Review
2018
Talimogene laherparepvec: First in class oncolytic virotherapy
ABSTRACT Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through… 
Review
2018
Review
2018
Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
BackgroundTalimogene laherparepvec (TVEC) is an oncolytic herpes virus used as intralesional therapy for patients with… 
2018
2018
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma
Talimogene laherparepvec is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy for the local treatment… 
Review
2017
Review
2017
A practical guide to the handling and administration of talimogene laherparepvec in Europe
Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus… 
2017
2017
Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases
Review
2016
Review
2016
Talimogene Laherparepvec for the Treatment of Advanced Melanoma
Talimogene laherparepvec (T-VEC) is a first-in-class oncolytic virus that mediates local and systemic antitumor activity by… 
Review
2016
Review
2016
Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
Talimogene laherparepvec (T-Vec) is the first live virus to be approved by the US Food and Drug Administration for the treatment… 
2013
2013
Use of a Tn5-based transposon system to create a cost-effective Zymomonas mobilis for ethanol production from lignocelluloses
BackgroundCurrent methods of ethanol production from lignocelluloses generate a mixture of sugars, primarily glucose and xylose… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)